I am excited to announce that we now have available the newest weight loss peptide:
Retatrutide, which is currently in phase 3 trials with Lilly Pharmaceuticals and is expected to be FDA-approved by next year.
Retatrutide is the first triple hormone receptor agonist developed and now provides another choice, in addition to Semaglutide (Ozempic/Wegovy) and Tirzepatide (Mounjaro/Zepbound). While Semaglutide works on a single hormone receptor and Tirzepatide works on 2, Retatrutide hits 3 different hormone receptors, which enhances the potency and effectiveness of the agent. Published studies indicate that 24% of obese patients taking retatrutide lost 30% of their excess body weight in 48 weeks and over 90% lost at least 10% of body weight.
Side effects are similar to those experienced with Semaglutide and Tirzepatide: nausea and gastrointestinal complaints are the most common, but only 7% of patients in a study published in The New England Journal of Medicine1 discontinued the medication due to adverse effects. Like the others, Retatrutide is taken by injection, once weekly and the dose is titrated, according to the clinical response and needs of each person.
It is expected that when Retatrutide is FDA-approved and made available by Lilly (trade name has not yet been announced), it will be quite expensive and possibly not covered by pharmacy benefit insurance plans, as is often the case with Semaglutide and Tirzepatide.
Indeed, demand for these peptide medications has been great and the costs are an issue. We have been able to obtain these and other peptides for you at a fraction of the retail, brand formulation costs, though currently, these remain fairly expensive products.
Of course, we still have available Semaglutide and Tirzepatide as part of our weight control program. If you would like to learn more about these therapies, please give us a call to arrange a consultation to address your specific needs, interests, and questions.
In Health,
David Lans
